Browsing by Publisher "De Gruyter"
Now showing items 1-2 of 2
Combined effect of midostaurin and sphingosine kinase-1 inhibitor on FMS-like tyrosine kinase 3 (FLT3) wild type acute myeloid leukemia cells (De Gruyter, 2022)Objectives Therapeutic potential of clinically approved FLT3 inhibitor midostaurin has been neglected in wild-type FLT3 positive acute myeloid leukemia (AML). Sphingosine kinase-1 (SK-1) having anti-proliferative functions ...
(De Gruyter, 2020)Economic policy and interest groups